Tech Session IV: Nanomedicine and Nanoscale Delivery (Focus: Nano)
Integrating MD simulations in the design and preparation of Ibrutinib (IBR)-loaded liposomes
Wednesday, July 16, 2025
3:05 PM – 3:16 PM EDT
Introduction: Ibrutinib is a BTK inhibitor used to treat certain blood cancers, such as CLL/(SLL and WM. The current oral drug products have high doses but a low bioavailability (2.9% in fasted conditions)1, significant side effects2,3, and severe adverse reactions which lead to discontinued treatment or reduced dosage1. Therefore, developing a drug delivery system that can enhance bioavailability, achieve controlled release, reduce dose, and minimize side effects is necessary and important. This advancement may potentially lead to a reduction in the required dose and reduced side effects
Learning Objectives:
At the completion of this activity, participants will know
Choose the most appropriate phospholipids for the design of the Ibrutinib liposome formulation.
Design a new delivery system to improve anti-cancer efficacy while minimizing side effects.
Check if the MD simulation can be an effective method of guiding the experimental work in practice.
